Health Anti-LAG-3, Pembrolizumab Doublet Continues to Impress in Metastatic NSCLC Eli Pacheco Jul 7, 2022 0 At the recent American Society of Clinical Oncology (ASCO) annual meeting, updated results of a phase II trial…
